Phenotype
|
Fish
|
Conditions
|
Figures
|
liver map1lc3b expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver atg4a expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver pnpla2 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver tfeb expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
whole organism triglyceride decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver casp9 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
liver gadd45aa expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 8
from Han et al., 2021
|
hepatocyte lipid droplet increased size, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 6
from Han et al., 2021
|
liver sqstm1 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver ulk1a expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver lipeb expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
whole organism icosapentaenoic acid increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver becn1 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver sqstm1 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver il6 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 8
from Han et al., 2021
|
liver map1lc3b expression decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver atg7 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver fatty acid decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 6
from Han et al., 2021
|
whole organism oxygen metabolic process decreased magnitude, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
whole organism octanoic acid increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver lipea expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver lamp1b expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver atf6 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: 3-methyladenine
|
Fig. 8
from Han et al., 2021
|
liver abhd5a expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
whole organism nonadecanoic acid increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver lipf expression decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
whole organism decreased weight, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 6
from Han et al., 2021
|
liver atg5 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver mt-atp6 expression decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 8
from Han et al., 2021
|
liver mt-cyb expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
whole organism tetradecanoic acid increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver plin2 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver mgll expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver cholesterol increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 6
from Han et al., 2021
|
liver ssbp1 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
liver casp3a expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
whole organism docosahexaenoic acid increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver xbp1 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: 3-methyladenine
|
Fig. 8
from Han et al., 2021
|
liver plin1 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver pnpla2 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver tfam expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
liver atg12 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
whole organism icosanoic acid increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
whole organism decanoic acid increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
whole organism protein decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 6
from Han et al., 2021
|
liver low-density lipoprotein increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 6
from Han et al., 2021
|
liver map1lc3b expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver ddit3 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 8
from Han et al., 2021
|
liver ulk1b expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver cholesterol increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 6
from Han et al., 2021
|
liver tnfa expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
liver vacuolated, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver ddit3 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
liver mt-atp6 expression amount, ameliorated
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
liver ulk1b expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
whole organism protein decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2,
Fig. 6
from Han et al., 2021
|
whole organism phosphatidylcholine increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver lamp1b expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7,
Fig. 8
from Han et al., 2021
|
whole organism phosphatidylethanolamine increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
whole organism hexadecenoic acid increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
whole organism decreased weight, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2,
Fig. 6
from Han et al., 2021
|
liver mgll expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
whole organism docosanoic acid decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver atg4a expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
whole organism lipid decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2,
Fig. 6
from Han et al., 2021
|
liver gadd45aa expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
liver yellow, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
hepatocyte mitochondrion increased size, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
liver tfeb expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver il1b expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
liver plin2 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver cav1 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver fatty acid decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 6
from Han et al., 2021
|
liver atg7 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver abhd5a expression amount, ameliorated
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
whole organism linoleic acid decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver lipf expression decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver vacuole increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver mt-nd1 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 8
from Han et al., 2021
|
whole organism pentadecanoic acid increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
liver tnfa expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 8
from Han et al., 2021
|
liver casp9 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 8
from Han et al., 2021
|
liver tfam expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 8
from Han et al., 2021
|
liver map1lc3b expression amount, ameliorated
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver becn1 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver cav1 expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 7
from Han et al., 2021
|
liver low-density lipoprotein increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 6
from Han et al., 2021
|
liver lipea expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
chemical treatment by diet: inhibitor
|
Fig. 7
from Han et al., 2021
|
liver il1b expression increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 8
from Han et al., 2021
|
swimming decreased linear velocity, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
whole organism elaidic acid decreased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|
whole organism (15Z)-tetracosenoic acid increased amount, abnormal
|
lipfecn5/ecn5 (AB)
|
standard conditions
|
Fig. 2
from Han et al., 2021
|